Sofinnova closes $540M crossover fund: Paris-based venture capital firm Sofinnova Partners has closed on a 445 million euro ($540 million) new fund, called the Sofinnova Crossover Fund, which will target late-stage biopharma and medtech investments. Depuis plus de 40 ans, la société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Sofinnova Partners 7-11 boulevard Haussmann 75009 Paris Tél. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Products. Sofinnova Investments has made 18 diversity investments. Advanced Search. Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. • With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies. Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, This profile is locked. Pricing. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Total Fund Raised $3B Sofinnova Partners has raised a total of $3B across 10 funds, their latest being Sofinnova Crossover Fund. Retrouvez le numéro de SIRET de SOFINNOVA PARTNERS mais aussi son SIREN et son numéro de TVA Intracommunautaire. Virtual biotech Antiva sets out on a big R&D … Sofinnova Ventures invests in Life Science and Technology start-ups. Meanwhile, a Crunchbase Pro list points to at least sixteen companies across the globe offering new models for healthcare visits that have raised venture funding in the last couple of years. SOFINNOVA PARTNERS est une entreprise de capital-risque indépendante, leader européen dans le financement de start-up, spin-off et opérations de retournement. Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Leighanne joined Sofinnova as an Analyst in 2019 focusing on public investments primarily in commercial-stage, global healthcare companies. SOFINNOVA PARTNERS, société par actions simplifiée, au capital social de 1600000,00 EURO, dont le siège social est situé au 7 BD HAUSSMANN, 75009 PARIS, immatriculée au Registre du Commerce et des Sociétés de Paris sous le numéro 413388596 représentée par M Antoine PAPIERNIK-BERKHAUER agissant et ayant les pouvoirs nécessaires en tant que président. Sofinnova Investments 's most notable exits include Invitae, Natera, and Humanigen. 017788 Petites-Affiches SOFINNOVA PARTNERS Société par actions simplifiée au capital de 1.600.000 € Siège social : 16-18, rue du 4-Septembre Immeuble Le Centorial 75002 PARIS 413 388 596 R.C.S. Save . 3000 Sand Hill Rd Building 4, Suite 250 Menlo Park, CA 94025 (650) 681-8420. Selon un rapport de Crunchbase, les fonds de capital-risque ont investi 772 millions de dollars depuis janvier 2016 dans des start-up de neurotechnologies, cherchant à réparer ou améliorer le fonctionnement du système nerveux. 7-11 boulevard Haussmann 75009 PARIS Tél. Our focus is on healthcare and sustainability. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to If you'd like to suggest changes to this profile, please email us at support@crunchbase.com, Descriptive keyword for an Organization (e.g. Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. Sofinnova promotes diversity in the workplace and believes diversity is a key component of its success. AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.. AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. Resources. Their professionals are seasoned business operators, possessing deep domain and investment expertise. Event. Sofinnova Ventures invests in Life Science and Technology start-ups. Search Crunchbase. If you decline, your information won’t be tracked when you visit this website. If you'd like to suggest changes to this profile, please email us at support@crunchbase.com, Descriptive keyword for an Organization (e.g. Spark Therapeutics is focused on the development of gene therapy. Subscribe to the Crunchbase Daily Volocopter raises $240M for electric air taxis Germany’s Volocopter, a developer of battery-powered electric air taxis, announced that it raised 200 million euros […] Angel, Fund of Funds, Venture Capital), General contact email for the organization. Depuis 40 ans, Sofinnova Partners a financé et accompagné près de 500 s Summary Financials Investments People Technology Signals & News. Jim Healy to Speak at Cancer Advance Boston. Connect to CRM . Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Build Query: Investments . SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Elle a accompagné les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Sofinnova Partners. Sofinnova Investments has had 100 exits. Jim Healy to Speak at Cancer Advance Boston . Sofinnova Capital VIII, entièrement investi, semble prendre la même voie. Angel, Fund of Funds, Venture Capital), General contact email for the organization, Early Stage Venture, Late Stage Venture, Seed, Venture Capital Investors with Investments in Rhone-Alpes, Seed Stage Investors with Investments in Greater Los Angeles Area, Late Stage Venture Investors with Investments in Irvine, California. Investment Firm. Robert Carroll. Products. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. They. Resources. La société vient de lever 333 millions d’euros pour Capital IX, qui cible des projets thérapeutiques en démarrage. Sofinnova Investments specializes in seed, startup, mid, early stage, series A, first venture round, and corporate spinouts. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital. Ce pionnier français du capital-risque fait évoluer sa gouvernance. 344506 Petites-Affiches SOFINNOVA CROSSOVER I UP Société par actions simplifiée au capital de 20 000 euros Siège social : 16-18 Rue du Quatre Septembre Immeuble Le Centorial 75002 PARIS 832 681 068 RCS PARIS Le Président en date du 4 mars 2019 a décidé de transférer le siège social de la société au 7-11 Boulevard Haussmann 75009 PARIS . Création : 1972 SA gérant des FCPR. Lucia Faccio joined Sofinnova Partners in 2018 as Partner for the Sofinnova Telethon Fund, Italy’s first biotechnology fund focused on rare and genetic diseases. positively impact its collective future. Sofinnova Partners lance un nouveau fonds dédié à la santé. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Active, Closed, This describes the type of investor this organization is (e.g. Try Pro free Solutions . Their most recent diversity investment was on Jun 4, 2020, when Athira Pharma raised $85M. 049252 Petites-Affiches SOFINNOVA SA ANCIENNEMENT SOCIETE POUR LE FINANCEMENT DE L'INNOVATION Société anonyme au capital de 38.051,60 € Siège social : Immeuble le Centorial 16-18, rue du Quatre-Septembre 75002 PARIS 722 003 001 R.C.S. Advanced Search. Search Crunchbase. Sofinnova. In that role, she focused on M&A, public […] Portfolio News. Le fonds précédent, levé en 2012, était de 240 millions d’euros. Active, Closed, Alternate or previous names for the organization, This describes the type of investor this organization is (e.g. Resources. Mar 28, 2017. 1250 Prospect Street, Ocean Level - 4 La Jolla, CA 92037 (858) 551-4880. Telephone (650) 681-8420 Fax (650) 322-2037. deals@sofinnova.com ir@sofinnova.com info@sofinnova.com Sofinnova. know how to help entrepreneurs build successful, global businesses. 1250 Prospect Street, Ocean Level - 4 La Jolla, CA 92037 (858) 551-4880. Sofinnova Partners, un leader du capital risque en Europe spécialisé dans les sciences de la vie, annonce avoir levé 300 millions d’euros pour son fonds Sofinnova Capital VIII dédié à la santé, soit un montant supérieur à l’objectif initial de 250 millions d’euros. Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Contact us for more information » Sofinnova. Log In. : 0176234100 E-mail : info@sofinnovapartners.com Web : www.sofinnova.fr Autre(s) bureau(x) : L'accès à l'annuaire est réservé aux membres Ou aux personnes ayant acheté un accès 3000 Sand Hill Road, Building 4, Suite 250 Menlo Park, CA 94025. Actionnariat : les associés. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 … Par Armelle Bohineust. Après le cinéma, l'agriculture, les transports, la Silicon Valley a un nouveau terrain de jeu : le cerveau. Save Search . A single cookie will be used in your browser to remember your preference not to be tracked. Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. Bring us the bold idea. Before joining Sofinnova, Leighanne was an investment banking analyst in the Healthcare group at Jefferies. Sofinnova Partners. Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership. We proactively source deals, take a lead role, and are often the first institutional investor in Round A financings. Log In. Here’s what you need to know today in startup and venture news, updated by the Crunchbase News staff throughout the day to keep you in the know. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved Investments . Bilan Gratuit de SOFINNOVA PARTNERS à PARIS (75009) sur SOCIETE.COM (413388596), chiffre d'affaire, résultat net, bénéfices, actif, passif, compte de résultat San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Lucia brings to Sofinnova Partners more Effectif 25 chargés d’investissement. Sofinnova, fer de lance du financement des start-up santé . In 2020 she transitioned to the Private Equity team to focus on biopharmaceutical investments. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to. Pricing. Sofinnova closes $650M biotech fund. 1250 Prospect Street, Ocean Level - 4 La Jolla, CA 92037 (858) 551-4880. Let's collaborate to try and change medicine today to transform lives in the future. View our portfolio of companies seeking to change lives. Sofinnova deploys human and financial capital to turn dreams into drugs. Try Pro free Solutions. Their professionals are seasoned business operators, possessing deep domain and investment expertise. SOFINNOVA PARTNERS ne comprenant aucun employé avec un capital de 1600 K euros. It was headquartered in Paris, Ile-de-France in 1972. Resources. This fund was announced on Mar 3, 2021 and raised a total of €445M. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. 3000 Sand Hill Rd Building 4, Suite 250 Menlo Park, CA 94025 (650) 681-8420. We encourage people with diverse backgrounds to apply. • Bpifrance* and CNP Assurances acted as sponsors for the fund. Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. Highlights. Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, This profile is locked. Get the most out of Crunchbase Since 2012, she has been Director of Research & Development at Fondazione Telethon, the second largest Italian Foundation dedicated to research. 3000 Sand Hill Rd Building 4, Suite 250 Menlo Park, CA 94025 (650) 681-8420. Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the close of its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333 million. Sofinnova Partners, investisseur historique majeur de Pixium Vision a été administrateur de la Société entre 2014 et 2017 et occupait un poste de censeur depuis 2017. Partner, Head of Investor Relations and Responsible Investment Strategy Sofinnova Partners invests across the entire value chain of life sciences investments, from seed to later-stage. Apr 11, 2017. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. SOFINNOVA SARL, société à responsabilité limitée, au capital social de 38051,60 EURO, dont le siège social est situé au 7 BD HAUSSMANN, 75009 PARIS, immatriculée au Registre du Commerce et des Sociétés de Paris sous le numéro 722003001 représentée par MME Monique SAULNIER agissant et ayant les pouvoirs nécessaires en tant que gérant. : 01 53 05 41 00 www.sofinnova.fr. Dans son dernier bilan (2017), les résultats sont de 6 à 9 M euros pour un chiffre d’affaire de 11 à 24 M euros. Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. • Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe. Contact Sofinnova today. Apply Now. In 2017, Sofinnova launched an all-cap, value-oriented, long/short global therapeutics hedge fund with an emphasis on mid and small-cap companies. Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership. Sofinnova, a biotech-focused venture and growth investor, has raised $650 million for its latest fund, Sofinnova Venture Partners X. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Sofinnova Investments Portfolio Companies, Venture Capital Investors with Investments in South San Francisco, California, Venture Capital Investors with Investments in Rhone-Alpes, Venture Capital Investors with Investments in Wisconsin. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Formation Expert Automobile Toulouse, Fil D'actualité Facebook Bloqué, Rugby France Irlande 2021, Attraction Movie Streaming, Commando Trépel Recrutement, Kevin Guedj Origine Israël,
Commentaires récents